好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Quality Improvement in Deep Brain Stimulation for Movement Disorders: Pandemic Influence on Highly Specialized "Elective" Surgery
Movement Disorders
P4 - Poster Session 4 (5:00 PM-6:00 PM)
5-024

To assess barriers in accessing Deep Brain Stimulation (DBS), as a function of the time required for each step of the workup and how the COVID-19 pandemic affected the timelines for access.

DBS is an effective and life-changing treatment for people with Parkinson’s disease (PD) in carefully selected patients. One of the major barriers to access is the wait time associated with an interdisciplinary workup process. Extended wait times could contribute to precipitated functional decline leading to loss of eligibility for DBS in addition to the lost time in quality-of-life improvements. We aim to assess access to DBS particularly related to the workup timeline. The second focus is to analyze the impact of COVID-19 pandemic on the DBS evaluation process and patients’ potential functional decline.

We set the decision to proceed with DBS as the start of the work-up and analyzed the timelines for implants from 2015 to 2022 at the University of Alberta. Specifically, we analyzed the time required to see other specialists and healthcare allies on the team and the impact COVID-19 had on access.
The total time from starting the work-up to DBS surgery was 387.76 ± 125.19 days prior to COVID-19, and marked delay occurred during and post-COVID-19 (839.78 ±  240.47 days). Most workups were done within 6 months, although a big range existed due to variable factors. The major delay to surgery was from consent to DBS. Pre-pandemic, no patients lost their candidacy status due to functional/cognitive decline during the work-up process. Further, the system has experienced difficulties in recovery even post-pandemic.

The impact of COVID-19 on DBS wait times and the consequences related to such have not been well studied in Canada. This study provided a first-hand account and encouraged further study and consideration to optimize access to DBS.
Authors/Disclosures
Fang Ba, MD (University of Alberta)
PRESENTER 		Dr. Ba has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen. The institution of Dr. Ba has received research support from Social Sciences and Humanities Research Council.
Pouria Torabi Mr. Torabi has received research support from Parkinson's Foundation. Mr. Torabi has received research support from Alberta Health Services Neurosciences, Rehabilitation & Vision Strategic Clinical Network.
Kevin C. Yen, MD (University of Alberta) Dr. Yen has received personal compensation in the range of $500-$4,999 for serving as a Guest Speaker with Abbvie.
Janis M. Miyasaki, MD, MEd, FAAN (University of Alberta/Alberta Health Services) Dr. Miyasaki has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for 好色先生. Dr. Miyasaki has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Oxford University Press. The institution of Dr. Miyasaki has received research support from PCORI. The institution of Dr. Miyasaki has received research support from Canadian Consortium on Neurodegeneration in Aging. The institution of Dr. Miyasaki has received research support from University Hospital Foundation. The institution of Dr. Miyasaki has received research support from Social Science and Health Research Council. The institution of Dr. Miyasaki has received research support from Parkinson Society Canada. The institution of Dr. Miyasaki has received research support from Parkinson Foundation. The institution of Dr. Miyasaki has received research support from Parkinson Foundation.
Tejas Sankar, MD, PhD Dr. Sankar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Boston Scientific. Dr. Sankar has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Canadian Journal of Neurological Sciences. The institution of Dr. Sankar has received research support from Canadian Institutes of Health Research.
Aakash S. Shetty, MD Dr. Shetty has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Shetty has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Parkinson Canada.